Zura Bio Accelerates Tibulizumab Trials with Oversubscribed Enrollment — Zura Bio Limited

Event summary

Zura Bio completed enrollment in Phase 2 TibuSHIELD trial for hidradenitis suppurativa (HS) with 247 participants, exceeding target.
Phase 2 TibuSURE trial for systemic sclerosis (SSc) also exceeded enrollment target of 80 participants.
Topline data from TibuSHIELD expected in Q4 2026; TibuSURE data anticipated in H1 2027.
Zura plans to initiate a third Phase 2 study for tibulizumab by year-end 2026.
$225.6 million in cash as of March 31, 2026, expected to fund operations through at least end of 2028.

The big picture

Zura Bio's oversubscribed enrollment in two Phase 2 trials highlights the unmet need for effective treatments in HS and SSc. The company's strategy of targeting dual pathways (IL-17 and BAFF) positions it to potentially break through efficacy ceilings in complex immune disorders. With plans to expand into a third indication, Zura is betting on the broad applicability of its bispecific mechanism across multiple autoimmune conditions.

What we're watching

Clinical Efficacy: Whether tibulizumab's dual IL-17 and BAFF inhibition can demonstrate superior efficacy in HS and SSc trials.
Pipeline Expansion: The pace at which Zura can successfully expand tibulizumab into a third immune-mediated indication by year-end 2026.
Financial Runway: How Zura's $225.6 million cash position will support operations through 2028 amid potential additional clinical studies.